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The epidermis is the outermost layer of the body and protects it from environmental insults. This crucial function is sustained by a
continuous process of self-renewal involving the carefully balanced proliferation and differentiation of progenitor cells constantly
replacing the mature cells at the surface of the epidermis. Genetic changes in the signalling pathways controlling keratinocyte
proliferation and differentiation disrupt this balance and lead to pathological changes including carcinogenesis. This review discusses
the role of Ras, an oncogene critically involved in the development of skin neoplasia, and its downstream effector Raf in epidermal
homeostasis and tumourigenesis. In particular, we will focus on the recently established role of Raf-1 as the decisive element that,
by restraining keratinocyte differentiation, allows the development and maintenance of Ras-driven tumours.
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The epidermis is the outer layer of the skin, a stratified squamous
epithelium that forms a protective barrier against environmental
insults and prevents body dehydration. The epidermis is primarily
composed of keratinocytes in which pigment cells (melanocytes),
immune cells (Langerhans cells and T cells) and nerve-ending cells
(Merkel cells) are embedded. Invaginating into the dermis, the
epidermis gives rise to various appendages: the hair, produced by
the hair follicles, the sebaceous glands that lubricate the skin and
the sweat glands that extrude water and salts (Figure 1A). The
epidermis is separated from the dermis by the basement
membrane, which is rich in extracellular matrix, and is organised
into four major layers: the stratum basale, the stratum spinosum,
the stratum granulosum and the stratum corneum. The stratum
basale contains the keratinocyte progenitors required for skin
renewal. These can either divide to generate further progenitor or
give rise to suprabasal keratinocytes (reviewed in Blanpain and
Fuchs, 2009). As they progress to the stratum spinosum and to the
stratum granulosum, the keratinocytes produce the network of
keratin filaments anchored in intercellular junctions that provide
structural support to the skin; the cells flatten and exocytose
lamellar granules containing the precursors of the lipids that
contribute to the stratum corneum barrier. The stratum corneum
contains the last stage of differentiation, the enucleated corneo-
cytes, which are continuously sloughed off and must be replaced
by differentiation of the lower layers (Figure 1B).
To preserve the integrity of the epidermal barrier, the epidermis
turns over throughout life. Alterations in this process, such as
keratinocyte proliferation/differentiation defects, or inflammation
can lead to cancer or skin barrier defects; thus, the many signalling
pathways involved in epidermal homeostasis must be tightly
controlled.
RAS PATHWAYS IN THE EPIDERMIS
The epidermal growth factor receptor (EGFR) is a critical regulator
of epidermal homeostasis (Figure 1C). Binding of EGFR to its
ligands, EGF, TGF-a and IGF, promotes keratinocyte proliferation;
in contrast, inhibitory ligands of EGFR, Lrig1 and Mig6 are
involved in maintaining stem cell quiescence, as ablation of either
protein leads to hyperproliferation of keratinocytes (Fuchs, 2009).
Downstream of EGFR, activation of Ras induces keratinocyte
proliferation and inhibits differentiation (Khavari and Rinn, 2007).
Ras isoforms are small G-nucleotide-binding proteins that oscillate
between a GDP-bound, inactive state, and a GTP-bound state in
which they can bind and activate their downstream effectors.
In growth factor signalling, the transition between the inactive and
the activated state is engendered by the binding of a guanine
nucleotide exchange factor (GEF) that displaces GDP. Once GDP is
displaced, GTP, whose intracellular concentration is ten-fold
higher than that of GDP, will bind to Ras, converting it into an
active form. Active Ras will then proceed to stimulate a number of
effectors, including the prominent classical effectors phospho-
inositide-3 kinase (PI-3K) and Raf; Ral-GDS and Tiam-1, exchange
factors leading to the activation of small GTPases Ral and Rac; and
several other less well-defined effectors (Figure 1C; Karnoub and
Weinberg, 2008). These molecules control aspects of keratinocyte
biology ranging from the regulation of proliferation, traditionally
attributed to the Raf/MEK/ERK pathway (see below), or of
survival, linked to the activation of PI-3K and its downstream
target Akt (Sibilia et al, 2000; Calautti et al, 2005) and Ral-GDS
(Gonzalez-Garcia et al, 2005), to the establishment of cell–cell
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(Mertens et al, 2005; Pegtel et al, 2007; Rygiel et al, 2008).
Thus, activation of the Ras pathway by growth factors must be
kept under tight control to provide just the right balance
of proliferation/differentiation signals required for epidermal
homeostasis.
Adhesion molecules, such as integrins and cadherins, have a
crucial role in the modulation of growth factor signalling in the
epidermis. In general, integrin activation supports proliferation,
whereas cadherins can both support or inhibit it (Figure 1C);
E-cadherin and desmosomal cadherins, for instance, modulate the
EGF response to signal growth arrest (Muller et al, 2008). In line
with its crucial role in proliferative signalling, the Ras pathway is
activated by integrins (Janes and Watt, 2006) and negatively
regulated by cell–cell adhesion: ablation of either a-catenin or
p120-catenin in the epidermis causes a reduction of adherens
junctions, which does not affect skin barrier and intercellular
adhesion but leads to hyperplasia and to sustained activation
of the Ras/ERK pathway (Vasioukhin et al, 2001; Perez-Moreno
et al, 2006).
Activating Ras mutations stabilise this signalling-competent,
GTP-bound state. These mutations are frequent in human cancer
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Figure 1 Ras pathways in the epidermis. (A) Schematic representation of mammalian skin. The skin consists of subcutaneous tissue, dermis and epidermis.
Hair follicles and sebaceous glands invaginate into the dermis. (B) Structure of the epidermis. The epidermis is mainly composed of keratinocytes in various
stages of differentiation. We distinguish four strata: the stratum basale, comprising the proliferating, undifferentiated basal keratinocytes; the strata spinosum
and granulosum, containing differentiating keratinocytes; and the stratum corneum, with the terminally differentiated, enucleated corneocytes that are
continuously removed and replaced by cells from the differentiating strata below. (C) The Ras pathway in the epidermis. Ras can be activated downstream
of the EGFR and integrins, and can be inhibited by adhesion molecules, such as E-cadherins, inducing growth arrest. With its host of downstream effectors,
Ras can mediate survival, proliferation, and can inhibit differentiation (see text for details). Arrows denote induction, blunt arrows indicate inhibition. Arrows
pointing upwards signify increase, and arrows pointing downwards symbolise decrease.
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www.sanger.ac.uk/genetics/CGP/cosmic). The number of tumours
(particularly squamous cell carcinomas) containing GTP-bound
Ras is however much higher, likely owing to the autocrine/
paracrine activation and/or to mutation in receptor tyrosine
kinases such as the EGFR (Khavari and Rinn, 2007). Expression of
constitutively active Ras mutants in the basal layer of mouse
epidermis induces proliferation and inhibits differentiation
(Vitale-Cross et al, 2004; Khavari and Rinn, 2007); the activation
of endogenous Ras by the transgenic expression of the Ras
GEFs SOS (Sibilia et al, 2000) and Rasgrp1 (Oki-Idouchi and
Lorenzo, 2007) in the same epidermal compartment produces
similar phenotypes. Consistent with an essential role of Ras in skin
tumourigenesis, H-Ras ablation impairs tumour development in
mouse models of chemical carcinogenesis (Ise et al, 2000).
The consequences of Ras activation in the epidermis can be
mimicked, at least in part, by the expression of gain-of-function
mutants of Ras downstream effectors. Constitutively active Akt
mutants promote proliferation in skin (Murayama et al, 2007);
conversely, the knock-in of a PI-3K mutant incapable of binding to
Ras reduces tumour load in a chemical model of epidermal
carcinogenesis (Gupta et al, 2007). Ablation of other Ras targets
such as Tiam1 (Malliri et al, 2002) and its downstream target Rac1
(Wang et al, 2010), Ral-GDS (Gonzalez-Garcia et al, 2005) and
PLCepsilon (Bai et al, 2004) has similar effects, but only in the case
of Rac1 it is clear that the phenotype is cell autonomous.
RAF PATHWAYS IN THE EPIDERMIS
The Raf/MEK/ERK cascade is the longest-studied and probably the
best-described Ras effector pathway. The term ‘cascade’ already
suggests the chain reaction that propels the signal, in the form
of sequential phosphorylation, from an entry point to an
intermediate kinase and finally to ERK, the business end of the
pathway. ERK stimulation results in the phosphorylation of
transcription factors, structural proteins and metabolic enzymes,
and ultimately engenders both short- and long-term changes
in cellular behaviour. This basic three-tiered module is robust and
plastic at the same time, allowing not only the amplification but also
the diversification and temporal modulation of the signal at each
and every node; in mammals, it is found in four mitogen-activated
protein kinase (MAPK) pathways that contribute to implementing
biological outcomes as diverse as proliferation, apoptosis, differ-
entiation, motility and response to stress and cytokines.
One outstanding feature of the Raf/MEK/ERK pathway in
mammals is redundancy. Mammals have three Raf isoforms
(A-Raf, B-Raf and Raf-1, also known as C-Raf), two MEK and two
ERK isoforms. All three Rafs can bind to Ras and phosphorylate
MEK, although B-Raf is much more efficient than the other two
and is necessary for ERK activation in vivo (reviewed in Galabova-
Kovacs et al, 2006a; Niault and Baccarini, 2010). Both MEKs can
phosphorylate ERK1/2; and whether ERK1/2 have non-redundant
functions or not is still unclear (see below).
Consistent with its prominent role as a MEK kinase, B-Raf is the
component of the ERK pathway most often mutated in human
tumours, with a particularly high frequency (43%) in human
melanoma. The most frequent B-Raf mutation, V600E, results in
constitutive catalytic activity and MEK/ERK activation. Recently, a
kinase drug selectively inhibiting B-Raf V600E has achieved an
unprecedented response rate of 80% in phase 1 clinical trials
involving metastatic melanoma patients, opening new therapeutic
avenues for this deadly disease (Bollag et al, 2010; Flaherty et al,
2010). Less frequent BRAF mutations reduce intrinsic catalytic
activity but drive MEK/ERK activation by stimulating the
formation of B-Raf/Raf-1 heterodimers in which mutant B-Raf
activates wild-type Raf-1 in trans (reviewed in Niault and
Baccarini, 2010; Wimmer and Baccarini, 2010).
Unlike B-Raf, Raf-1 is infrequently mutated in human cancer
(overall frequency of 1%; http://www.sanger.ac.uk/genetics/CGP/
cosmic). The rare mutations detected in human cancer cell lines
and in patients with therapy-related acute myeloid leukaemia do
not drive tumourigenesis per se, but can do so upon somatic loss of
a negative regulator of Raf-mediated MEK/ERK activation, the Raf
kinase inhibitory protein RKIP (Niault and Baccarini, 2010).
Interestingly, RKIP promotes differentiation of human keratino-
cytes (Yamazaki et al, 2004), and both RKIP and B-Raf are
downregulated in human SCC (Zaravinos et al, 2009), whereas
Raf-1 is overexpressed (Riva et al, 1995). Mutations or over-
expression of MEK or ERK in human SCC have not been reported.
The data summarised above suggest that Raf-1 is an important
player in the development of human SCC. Support for this idea
came in the unexpected form of recent findings concerning small-
molecule inhibitors of Raf. These compounds, some of which are
already being used in the clinic, efficiently inhibit MEK/ERK
activation in cells harbouring the B-Raf V600E mutation (Bollag
et al, 2010; Flaherty et al, 2010), but can activate the ERK pathway
to different extents in normal cells and in cells expressing Ras
mutations. At the molecular level, the inhibitors promote the
formation of dimers in which wild-type Raf-1 is activated in trans
(reviewed in Brower, 2010; Cichowski and Janne, 2010; Wimmer
and Baccarini, 2010). Before these reports, potentially deleterious
effects of Raf inhibitors because of ERK inhibition in normal cells
were expected to limit their clinical use. In stark contrast, these
studies now predict that these inhibitors may be dangerous
because they may activate Raf-1 and MEK/ERK in B-Raf wild-type
cells prone to deregulated proliferation because of other muta-
tions. Intriguingly, although the inhibitors are administered
systemically, keratoacanthomas and SCC in situ develop in
patients treated with Raf inhibitors (Brower, 2010; Cichowski
and Janne, 2010; Wimmer and Baccarini, 2010), underscoring the
connection between Raf-1 activation and epidermal proliferation
and tumourigenesis.
The role of the Raf/MEK/ERK pathway in epidermal prolifera-
tion has been clearly established in animal models, in which
inducible activation of Raf or MEK in the epidermis results
in massive cutaneous hyperplasia and reduced differentiation
(Khavari and Rinn, 2007). In apparent contrast, knockout of
B-Raf (Galabova-Kovacs et al, 2006b), Raf-1 (Ehrenreiter et al,
2005), MEK1, MEK2 (Scholl et al, 2007), ERK1 and ERK2 (Dumesic
et al, 2009) has no effect on epidermis development and/or
homeostasis. In the MEK and ERK knockouts, this lack of phenotype
may result from functional redundancy within the pathway. Indeed,
epidermis-restricted compound MEK1/MEK2 knockout causes
severe barrier function defects and marked epidermis hypoplasia
leading to perinatal death (Scholl et al, 2007); and simultaneous
ERK1/ERK2 ablation inhibits keratinocyte division (Dumesic et al,
2009). MEK1/2 gene dosage also appears to be the rate-limiting
factor in the hyperplastic response of mouse epidermis to activated
Ras (Scholl et al, 2009a); in contrast, however, MEK1 (but not MEK2)
and ERK1 are required for full-fledged chemical carcinogenesis
(Bourcier et al,2 0 0 6 ;S c h o l let al, 2009b). Together, these results
confirm the role of the ERK pathway in promoting proliferation and
restraining differentiation in the epidermis.
However, recent conditional gene ablation experiments have
revealed that one of the Raf kinases has ERK-independent roles in
keratinocyte biology and tumourigenesis. As mentioned above,
mice harbouring epidermis-restricted Raf-1 ablation do not show
any major anomalies, with the exception of a curly fur and
whiskers that subside after the first hair cycle. Wound healing,
however, is delayed in these mice, and their keratinocytes show
defects in adhesion and migration (Ehrenreiter et al, 2005). These
phenotypes do not correlate with defects in ERK phosphorylation;
rather, we have been able to trace them to the cytoskeleton-based
Rho effector Rok-a, which is hyperactive in Raf-1-deficient cells
(Ehrenreiter et al, 2005, 2009; Niault et al, 2009).
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function(s) connected with its ability to phosphorylate MEK or
other substrates, they do indicate that the essential role of Raf-1, at
least in the epidermis, is independent of its kinase activity. But
what happens if one stresses the system, for instance, by inducing
tumourigenesis in vivo? We have answered this question by
combining a chemical and a genetic tumourigenesis protocol with
epidermis-restricted Raf-1 ablation in mice. Both models rely on
the activation of Ras, caused by mutations in the DMBA/TPA
chemical carcinogenesis model (Ise et al, 2000) or by tethering
the Ras activator SOS to the membrane of basal keratinocytes
(Sibilia et al, 2000); this results in the constitutive activation
of endogenous Ras, observed more frequently than Ras mutations
in human SCC (Dajee et al, 2003). The results were striking: Raf-1-
deficient epidermis was completely refractory to tumour formation
in both models; in addition, using the genetic model we could
show that Raf-1 ablation enforces complete, rapid regression of
established lesions that never recur, although Ras activation
persists throughout the life of the animals (Figure 2; Ehrenreiter
et al, 2009). Tumour regression is characterised by massive,
runaway differentiation, which was a surprise in view of the well-
established role of Raf-1 in proliferation and of its essential
antiapoptotic function in other cell types (Galabova-Kovacs et al,
2006a). These data identify Raf-1 as the single key Ras effector
absolutely required for both development and maintenance of Ras-
driven tumours in vivo. They evoke the concept of ‘non-oncogene
addiction’, intended as the absolute dependence of cancer cells
on a non-mutated component of a signalling pathway to prevent
system failure in the form of apoptosis or, as in this case,
differentiation. Downstream of Ras, activated Raf-1 binds to
Rok-a, reducing its activity (Figure 2); Rok-a, in turn, has been
previously implicated in keratinocyte differentiation (McMullan
et al, 2003) and, via the phosphorylation of Cofilin, can prevent the
activation of the STAT3/Myc axis (Honma et al, 2006).
The relevance of the Raf-1/Rok-a interaction for tumourigenesis
is illustrated by the fact that Ras-driven dedifferentiation, STAT3
phosphorylation and Myc expression occur both in wild-type and
in Raf-1-deficient epidermis treated with a chemical Rok inhibitor
(Ehrenreiter et al, 2009). These data establish Raf-1 as an
endogenous Rok-a inhibitor operating downstream of Ras
to regulate keratinocyte differentiation, and imply that caution is
in order when using Rok inhibitors, especially in the treatment of
Ras-driven tumours (Figure 2).
Rok-a inhibition by Raf-1 requires physical interaction between
the two proteins. In growth factor-stimulated or Ras-transformed
cells, the kinase domain of Rok-a interacts with, and is inhibited
by, the regulatory domain of Raf-1, which is structurally very
similar to Rok-a’s own autoinhibitory domain (Niault et al, 2009).
This kind of ‘inhibition in trans’ has never been reported before,
and represents a new paradigm of kinase regulation and pathway
cross-talk.
Our results have implications for future therapeutic strategies
targeting the Raf-1/Rok-a interaction, for instance, by silencing
the Raf-1 gene or by using small-molecule inhibitors to disrupt the
complex. The predicted outcome of such interventions is an
increase in Rok-a activity, resulting in turn in epithelial cell
differentiation. The success of these therapies, however, might be
highly context dependent. We must bear in mind that Rok-a was
found upregulated in human SSC samples, and that its over-
expression confers features of malignancy to human tumours
in mouse xenograft models (Lefort et al, 2007). It is possible
that treatments aimed at increasing Rok-a activation might be
beneficial only in the context of epithelial tumours driven by Ras
activation. Alternatively, tumour cells might accumulate muta-
tions, downstream of Rok-a or in other pathways, which enable
them to tolerate high Rok-a activity without undergoing differ-
entiation. Thus, as in the case of other approaches, the success of a
Rok-a activation therapy might depend both on the type of tumour
and on the stage of the tumour at the time of intervention.
CONCLUSIONS
The evidence summarised above is consistent with a pivotal role
of Ras and its downstream effectors in epidermal tumourigenesis.
Ras effectors have been reported to induce proliferation and
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Figure 2 Ras-driven tumours are addicted to Raf-1. Ras-driven tumours, induced by the keratinocyte-restricted expression of membrane-tethered SOS
(SOS-F transgenic mice; red, irregularly shaped tail) regress upon keratinocyte-specific ablation of Raf-1, indicating an essential role of this molecule in tumour
maintenance. Downstream of Ras, Raf-1 is involved in at least two pathways: the canonical Raf/MEK/ERK pathway, where Raf-1 acts as an activator, likely in
the context of a Ras-induced heterodimer with B-Raf; and the Rok-a pathway, where Raf-1 acts as an inhibitor via direct protein–protein interaction
(left panel). Upon Raf-1 ablation (right panel; Raf-1 crossed out), ERK phosphorylation continues undisturbed, likely sustained by B-Raf; Rok-a, however,
is strongly activated, leading to increased differentiation, and to tumour regression.
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by Raf-1-mediated Rok-a has been added to the potentially
‘druggable’ events required for Ras-driven tumourigenesis. The
prediction of our in vivo work is that freeing Rok-a from its
interaction with Raf-1, for instance, by silencing the Raf-1 gene or
by using small-molecule inhibitors aimed to disrupt the complex,
will increase Rok-a activity and result in epithelial cell differentia-
tion, at least within a window of opportunity. Such a strategy
should be useful in the co-therapy of Ras-driven epidermis
tumours, much in the way that differentiation therapy has radically
increased the success rate of leukaemia treatment (Wang and
Chen, 2008).
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